Universal health coverage (UHC) is about ensuring that everyone, especially the most vulnerable, has access to the quality health care they need without suffering financial hardship. It is key to ...
Barcelona midfielder Dani Olmo is currently facing a period of uncertainty that could lead to an unexpected twist in his career. As a result, according to a recent report from Fichajes, Manchester ...
A recent report from AS highlights that the Barcelona squad has identified the Spanish Super Cup as a key objective for the season. The team is placing significant importance on this title, and it ...
Channel Nine have released the first trailer for the upcoming season, and it looks like next year will be every bit as intense and drama-filled as years past – maybe even more so. The teaser ...
Ukraine has developed a laser weapon capable of shooting down targets from more than a mile away, the country’s drone force commander has claimed Speaking at a defense summit in Kyiv this week ...
Viridian is progressing with two additional phase 3 trials, REVEAL-1 and REVEAL-2, with topline data anticipated in 2026. Viridian Therapeutics has announced topline data from THRIVE-2, (NCT06021054) ...
10 analysts have expressed a variety of opinions on Viridian Therapeutics (NASDAQ:VRDN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...
Ukraine has been deploying a new Tryzub ("Trident" in Ukrainian) laser capable of shooting down an aircraft, according to Interfax-Ukraine. Colonel Vadym Sukharevsky, commander of the Unmanned ...
Credit: mToa55 via Shutterstock. Viridian Therapeutics’s stock has jumped after a Phase III trial of veligrotug met all endpoints and was well tolerated in patients with chronic thyroid eye disease ...
Maddy is an editor and writer at IFLScience, with a degree in biochemistry from the University of York.
Viridian Therapeutics’ stock jumped Monday after the company unveiled another Phase 3 look at its potential competitor to Amgen’s Tepezza in thyroid eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback